Gene test could personalize breast cancer prevention drug

NCT ID NCT06062810

Ongoing Knowledge-focused Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study examines how genetic variations (SNPs) in certain genes influence how well the drug raloxifene works and its side effects in 600 patients with lobular carcinoma in situ (LCIS), a high-risk breast condition. Participants take raloxifene daily, and researchers sequence their DNA to find links between genes and treatment outcomes. The goal is to make raloxifene therapy more personalized and safer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Raloxifene
What this could lead to: If successful, this could help doctors predict which patients will benefit most from raloxifene and who might experience side effects, leading to more personalized treatment.
What could go wrong: This is an early-stage genetic analysis, not a test of a new drug. The findings may not change current practice or may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm lobular breast carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701

Rockville, Maryland, 20853, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.